Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS | $1.7 | $1.8 | $2.5 | $2.7 | ($1.9) | $3.9 | $4.6 | $3.9 | $3.7 | $4.3 | $2.2 | $2.3 | $2.6 | ($0.2) | $3.1 | $5.0 | $6.8 | $6.2 | $6.9 | $5.8 |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Eli Lilly and Company's last 12-month EPS is $9.2, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Eli Lilly and Company's EPS growth was 69.0%. The average annual EPS growth rates for Eli Lilly and Company have been 11.6% over the past three years, 2.3% over the past five years.
Over the last year, Eli Lilly and Company's EPS growth was 69.0%, which is higher than industry growth of (0.2%). It indicates that Eli Lilly and Company's EPS growth is Good.